Can EBV Cause a False Positive Lyme Disease Test? Understanding Cross Reactivity
Epstein Barr virus and Lyme disease can cause surprisingly similar symptoms. Fatigue, neurological complaints, body pain, swollen lymph nodes, cognitive changes, and a general feeling of being unwell can occur with either infection. For people experiencing persistent or unexplained symptoms, laboratory testing is often an important part of trying to understand what may be happening. But there is another complication that many patients don’t know about.
Epstein Barr virus, commonly called EBV, can sometimes contribute to a false positive Lyme disease antibody test because antibodies produced by the immune system may react with antigens used in Lyme testing.
This phenomenon is known as cross-reactivity.
Understanding cross-reactivity matters because a positive laboratory result does not always have a simple interpretation. It also does not mean that a positive Lyme disease test should automatically be dismissed simply because EBV is present.
The full clinical picture matters. Read The Clinical Diagnosis Guide Here.
Can EBV Cause a False Positive Lyme Disease Test?
Yes.
Epstein Barr virus infection has been associated with false-positive results on some Lyme disease antibody tests. The Centers for Disease Control and Prevention notes that false-positive cross-reactions can occur in people with several other conditions, including Epstein Barr virus infection. Research has also demonstrated that antibodies in people with active viral infections can react with Borrelia antigens used in Lyme disease testing.
This does not mean that EBV causes every questionable Lyme disease test result, nor does it mean that someone who tests positive for both EBV and Lyme disease necessarily has only one infection. Instead, it highlights an important limitation of antibody testing. Laboratory results must be interpreted alongside symptoms, medical history, potential tick exposure, timing of illness, and other relevant findings.
What Is Cross-Reactivity?
Cross-reactivity occurs when an antibody produced in response to one antigen also recognizes another antigen that has a sufficiently similar structure. Antibodies are designed to identify specific molecular targets. However, biological molecules are complex, and completely unrelated organisms can sometimes contain structures that resemble one another. An antibody produced during one infection may therefore react with an antigen used to test for another infection.
In Lyme disease testing, researchers have documented cross-reactions involving antibodies associated with infections such as Epstein Barr virus, cytomegalovirus, tick-borne relapsing fever (B. myamotoi), syphilis and Yersinia enterocolitica. Certain autoimmune conditions can also contribute to nonspecific antibody reactions.
This is one reason Lyme disease laboratory results should not be interpreted in isolation.
Why Can EBV Interfere With Lyme Disease Testing?
The immune response to an active viral infection can be extensive. During infections such as EBV, the immune system produces large numbers of antibodies and activates multiple immune pathways. This increased immune activity can sometimes produce antibodies that react nonspecifically with antigens used in laboratory tests. Research examining patients with active EBV, cytomegalovirus, and other viral infections has found cross-reactive responses to Borrelia antigens. Some Borrelia proteins appear to be particularly susceptible to these reactions. Researchers have identified proteins and peptides including OspC and flagellar proteins among antigens that may show cross-reactivity in certain circumstances. This does not make Lyme disease antibody testing useless. It means interpretation requires context and an understanding of what the test is actually measuring.
Lyme Disease Tests Usually Measure Your Immune Response
One of the most important things to understand about Lyme disease testing is that many commonly used tests do not look directly for living Borrelia bacteria. Instead, they measure antibodies produced by the immune system in response to Borrelia burgdorferi. This distinction matters.
Antibodies can take time to develop after infection. They can also remain detectable long after the initial infection occurred. According to the CDC, Lyme disease antibodies may take several weeks to develop and can remain elevated for months or years. Antibody levels, therefore, cannot be used by themselves to determine whether an infection has been cured.
The immune response is providing evidence about what it has recognized. A clinician still has to determine what that evidence means in the context of the patient.
EBV and Lyme Disease Can Also Look Similar
Laboratory cross-reactivity is only part of the challenge. EBV and Lyme disease can produce overlapping symptoms. People with either condition may experience symptoms such as:
Fatigue
Headache
Muscle or joint pain
Cognitive difficulties
Swollen lymph nodes
Neurological symptoms
Sleep disruption
A prolonged feeling of illness or reduced stamina
The similarity becomes particularly important when someone does not have an obvious erythema migrans rash or does not remember a tick bite.
EBV is also extremely common. Most adults have been infected with Epstein Barr virus at some point in their lives. This means the presence of EBV antibodies must also be interpreted according to which antibodies are elevated and the overall antibody pattern. However, cross-reactivity between EBV and Borrelia is observed mainly during EBV reactivation that is seen in a very small percentage of the population when their immune system is not functioning at its best.
A positive EBV antibody result does not automatically mean someone currently has an active EBV infection. Therefore, the interpretation of EBV lab results should also be done by experts who can differentiate between natural immunity and EBV reactivation.
What Do EBV Antibodies Mean?
EBV testing can include several different antibodies rather than a single positive or negative result.
Common markers include:
EBV Viral Capsid Antigen IgM. This antibody typically appears early during infection and usually declines. Its elevation that indicates ongoing viral infection.
EBV Viral Capsid Antigen IgG. This antibody develops during infection and generally remains detectable for life. It is detected in up to 97 percent of the healthy population.
EBV Nuclear Antigen antibodies. These usually develop later and can help distinguish previous exposure from a recent infection if IgM is elevated. But very similar to VCA IgG, EBNA IgG elevation is observed in more than 95% of healthy subjects.
EBV Early Antigen antibodies. The most important antibody that is present and is the best indication of EBV reactivation. These may provide additional information about the immune response to EBV, although interpretation can be more complicated.
Looking at an antibody pattern can provide substantially more information than simply being told that someone is “EBV positive.” Because overall, more than 90% of the healthy population are positive for EBV VCA IgG and EBNA IgG and not IgM.
Could Someone Have Both EBV and Lyme Disease?
Yes.
Finding evidence of EBV does not rule out Lyme disease. A person may have prior EBV exposure, a current or recent EBV infection, Lyme disease, or potentially evidence relating to both organisms. This is why automatically labeling a Lyme disease result as a false positive because EBV antibodies are detected can create another diagnostic problem. Published case reports have described situations in which Lyme disease and infectious mononucleosis created confusing laboratory findings. Researchers have cautioned that known cross-reactivity can sometimes cause clinicians to dismiss Lyme serology too quickly. The goal should therefore not be to decide that one laboratory result invalidates another. The goal is to understand the complete pattern.
Why IgM Results Require Particular Care
Lyme disease testing commonly evaluates IgM and IgG antibodies.
IgM antibodies tend to appear earlier in an immune response, while IgG antibodies generally develop later.
IgM results can also be more vulnerable to nonspecific reactivity.
For this reason, timing matters when Lyme disease testing is interpreted.
The CDC recommends disregarding positive Lyme IgM results when a patient has been ill for more than 30 days because interpreting IgM later in illness increases the risk of a misleading result. This is another example of why reading a laboratory report without knowing the timing and clinical history can lead to incorrect conclusions.
What Is Molecular Mimicry?
Cross-reactivity is closely related to another concept frequently discussed in immunology called molecular mimicry.
Molecular mimicry occurs when structures belonging to an infectious organism resemble structures found elsewhere, including structures within human tissue.
The immune system may generate antibodies or immune cells against the infectious organism that can also recognize similar molecular structures.
Scientists have studied molecular mimicry as one potential mechanism connecting certain infections with autoimmune reactions. One of the best examples of molecular mimicry is between EBV and brain tissue antigens that are involved in the pathogenesis of Multiple Sclerosis. There was a very interesting article published in the Journal of PNAS 2026. It explained that there is a specific sequence in an EBV peptide and its cross-reaction with Glial Cell Adhesion molecule, Alpha B Crystallin, and Anoctamin-2 and how they play a distinct role in the induction of Multiple Sclerosis. They concluded that based on molecular mimicry between EBV and brain tissue antigens, EBV has inseparable components of MS.
This field is particularly relevant to the work of Immunosciences Lab, where testing and research focus not only on infectious antibodies but also on immune reactions associated with autoimmunity and chronic inflammatory conditions.
How Immunosciences Lab Approaches Viral and Lyme Testing
Immunosciences Lab specializes in immunology testing related to Lyme disease, viral infections, autoimmunity, and chronic inflammatory conditions.
Its viral testing options evaluate several viruses that may be relevant when investigating complicated immune presentations.
Depending on the panel, Immunosciences Lab evaluates markers associated with Epstein Barr virus, cytomegalovirus, herpes simplex virus, human herpesvirus 6, and other viral infections. Very recently, in last month’s issue in Nature, scientists showed that these Herpes family viruses participate in acute as well as Long Covid-19.
Its more comprehensive viral panels include multiple EBV antibodies rather than relying on a single EBV marker. These may include EBV Viral Capsid Antigen IgG and IgM, EBV Early Antigen, and EBV Nuclear Antigen antibodies.
Immunosciences Lab also offers testing focused specifically on Lyme disease and immune responses to Borrelia antigens.
For patients with complicated histories, the potential value of broader testing is not simply finding another positive result. It is giving the treating healthcare practitioner additional information that can be considered alongside symptoms, history, physical findings, and other laboratory results.
Questions to Ask When Lyme and EBV Results Are Both Positive
If testing shows antibodies associated with both Lyme disease and EBV, it may be helpful to discuss several questions with a knowledgeable healthcare practitioner.
Which Lyme antibodies were positive?
Was the Lyme result based primarily on IgM, IgG, or both?
How long has the person been experiencing symptoms?
What does the complete EBV antibody pattern show?
Is there evidence suggesting recent EBV infection, previous exposure, or another immune pattern that may contribute to autoimmune diseases such as MS?
Does the person have a history of tick exposure?
Are the symptoms consistent with Lyme disease, EBV, another infection, or more than one condition?
Could cross reactivity be affecting any of the laboratory findings?
Are additional tests appropriate before reaching a diagnosis?
These questions help shift the conversation away from treating individual laboratory markers as definitive answers.
A Positive Test Is One Piece of a Much Larger Puzzle
Laboratory testing is enormously useful, but antibody testing measures the interaction between an organism and the immune system. That interaction can be complicated. EBV is one example of why Lyme disease test interpretation requires more than seeing the word “positive” on a laboratory report.
Cross-reactive antibodies can occur. Viral infections can influence immune activity. Antibodies can persist long after exposure. Symptoms can overlap between different illnesses. More than one condition can also exist at the same time.
The most useful question is therefore rarely, “Is this laboratory result positive?” A better question is, “What does this laboratory result mean when we consider everything else we know about this person?” That is where careful clinical interpretation becomes essential.
The Bottom Line
Epstein Barr virus can complicate Lyme disease testing.
Research has demonstrated that antibodies associated with viral infections, including EBV, can cross react with Borrelia antigens used in Lyme disease serology. That can contribute to false positive results in some people.
But cross-reactivity should not become a reason to automatically disregard Lyme disease either.
An accurate interpretation requires looking at which antibodies are present, when symptoms began, potential exposure history, the complete clinical presentation, and other laboratory findings.
For people navigating complicated chronic illness, understanding these nuances can make laboratory testing much more useful and help patients have better informed conversations with their healthcare practitioners.
This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Laboratory findings should be interpreted by a qualified healthcare professional in the context of an individual patient’s medical history, symptoms, and other clinical information.
Frequently Asked Questions About EBV and Lyme Disease Testing
-
Yes. EBV infection is one of several conditions known to produce cross reactive antibodies that may contribute to false positive Lyme disease serology. However, the presence of EBV does not prove that a Lyme disease result is false.
-
During viral infection, the immune system produces antibodies that can sometimes recognize similar molecular structures found in other organisms or laboratory antigens. This can result in cross reactivity.
-
Not necessarily. Most adults have been exposed to EBV, and certain EBV antibodies can remain detectable for life. The pattern of antibodies, symptoms, medical history, and other findings help determine the significance of a result.
-
Yes. Evidence of EBV does not rule out Lyme disease, and the presence of Lyme antibodies does not rule out EBV. Results need to be interpreted individually and in context.
-
Yes. Both conditions can be associated with fatigue, headache, body pain, cognitive symptoms, neurological complaints, and prolonged illness. The degree of overlap is another reason laboratory results should be considered alongside the complete clinical picture.
-
Cross reactivity happens when an antibody generated against one antigen also reacts with another antigen because the two structures share molecular similarities.
-
Immunosciences Lab offers specialized testing related to Lyme disease, viral infections, autoimmunity, and other immune mediated conditions. Its viral panels can include multiple EBV markers as well as antibodies associated with viruses such as CMV, HSV, and HHV 6.